Stock of the Day

September 23, 2021

BeiGene (BGNE)

$0.00
$0.00 (0.0%)
Market Cap: $18.03B

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BeiGene Bull Case

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

  • Current stock price is $191.78, indicating a strong market position and potential for growth.
  • Institutional ownership is at 49.13%, suggesting confidence from large investors in the company's future performance.
  • Recent increase in shares shorted from 1,860,000 to 2,010,000 indicates growing interest in the stock, which could lead to increased volatility and potential profit opportunities.
  • Average daily volume of 271,300 shares shows healthy trading activity, which can provide liquidity for investors looking to enter or exit positions.
  • Despite a 52-week performance decline of 5.44%, the company has the potential for recovery, making it a candidate for value investing.

BeiGene Bear Case

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

  • Short percentage of float is 0%, indicating that there is no significant short interest, which may suggest a lack of bearish sentiment or potential for price correction.
  • Recent month-to-month change in shares shorted is 11.94%, which could indicate increasing bearish sentiment among investors.
  • Outstanding shares total 92,010,000, which may dilute earnings per share and affect overall profitability.
  • Fifty-two week performance shows a decline of 5.44%, raising concerns about the company's recent performance and market competitiveness.
  • Days to cover is 8.3, which may indicate that it could take a significant amount of time for short sellers to cover their positions, potentially leading to price pressure.

Recent News